27 related articles for article (PubMed ID: 3494157)
1. Biochemical changes in tissue catecholamines and serotonin in duodenal ulceration caused by cysteamine or propionitrile in the rat.
Szabo S; Horner HC; Maull H; Schnoor J; Chiueh CC; Palkovits M
J Pharmacol Exp Ther; 1987 Mar; 240(3):871-8. PubMed ID: 3559978
[TBL] [Abstract][Full Text] [Related]
2. Effect of dopamine-related drugs on duodenal ulcer induced by cysteamine or propionitrile: prevention and aggravation may not be mediated by gastrointestinal secretory changes in the rat.
Gallagher G; Brown A; Szabo S
J Pharmacol Exp Ther; 1987 Mar; 240(3):883-9. PubMed ID: 3559980
[TBL] [Abstract][Full Text] [Related]
3. Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
Szabo S; Brown A; Pihan G; Dali H; Neumeyer JL
Proc Soc Exp Biol Med; 1985 Dec; 180(3):567-71. PubMed ID: 2417250
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of duodenal ulcer. Gastric hyperacidity caused by propionitrile and cysteamine in rats.
Szabo S; Reynolds ES; Lictenberger LM; Haith LR; Dzau VJ
Res Commun Chem Pathol Pharmacol; 1977 Feb; 16(2):311-23. PubMed ID: 847287
[TBL] [Abstract][Full Text] [Related]
5. Evidence for the involvement of dopamine agonists and antagonists in duodenal ulcer disease.
Neumeyer JL; Szabo S
Klin Wochenschr; 1986; 64 Suppl 7():123-7. PubMed ID: 3494157
[TBL] [Abstract][Full Text] [Related]
6. From cysteamine to MPTP: structure-activity studies with duodenal ulcerogens.
Szabo S; Cho CH
Toxicol Pathol; 1988; 16(2):205-12. PubMed ID: 3055230
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of duodenal ulcer disease.
Szabo S
Lab Invest; 1984 Aug; 51(2):121-47. PubMed ID: 6205219
[No Abstract] [Full Text] [Related]
8. Development and significance of cysteamine and propionitrile models of duodenal ulcer.
Szabo S; Pihan G
Chronobiol Int; 1987; 4(1):31-42. PubMed ID: 3315259
[TBL] [Abstract][Full Text] [Related]
9. From Selye's and Szabo's Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities.
Sikiric P; Boban Blagaic A; Krezic I; Zizek H; Kalogjera L; Smoday IM; Vukovic V; Oroz K; Chiddenton HM; Buric S; Antunovic M; Gojkovic S; Strbe S; Skocic M; Sikiric S; Milavic M; Beketic Oreskovic L; Kokot A; Koprivanac A; Dobric I; Sever M; Staresinic M; Batelja Vuletic L; Skrtic A; Seiwerth S
Pharmaceuticals (Basel); 2023 Dec; 16(12):. PubMed ID: 38139825
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
